Latest 2 Cases: DePuy Synthes Products, Inc. v. Veterinary Orthopedic Implants, Inc. (Civil Procedure), Mylan Laboratories Ltd. v. Janssen ...

The Oprah Interview as a Truth Commission

LESLEY WEXLER

Illinois Law professor Lesley Wexler explains how Oprah’s interview with Prince Harry and Meghan Markle might illuminate how a formal truth commission to deal with legacies of racism and colonialism might function in the British empire. Professor Wexler describes the purpose and function of state-operated truth commissions and notes the similarities and differences between those and the interview.

Read More

DePuy Synthes Products, Inc. v. Veterinary Orthopedic Implants, Inc.

Docket: 20-1514

Opinion Date: March 12, 2021

Judge: Timothy B. Dyk

Areas of Law: Civil Procedure, Intellectual Property, Patents

The parties compete in the market for veterinary orthopedic implants. DePuy sued VOI, alleging patent infringement. The district court entered the parties’ joint proposed protective order, designating certain information as “Confidential Material” and “Highly Confidential Material—Attorney Eyes Only.” The information designated “Highly Confidential” encompassed “supplier . . . names and identifying information.” DePuy filed under seal an unopposed motion for leave to amend the complaint to join as a defendant the manufacturer of VOI’s accused products, disclosing the manufacturer’s identity and information about the business relationship between the manufacturer and VOI. According to VOI, the manufacturer identity and other information are Highly Confidential and constitute trade secrets, so that it was necessary to file the amended complaint under seal, with only a redacted version publicly available. DePuy argued that the manufacturer’s public website advertises its business; that VOI and the manufacturer have no confidentiality agreement; that the manufacturer ships its products to VOI using a public carrier; and that a third party was aware that the manufacturer supplied products to VOI. The district court ordered that the amended complaint be filed on the public record without redaction of either the manufacturer's identity or other information. The order did not specifically analyze the other information. The Federal Circuit affirmed. The district court did not abuse its discretion in performing its obligation to ensure public access to court documents.

Mylan Laboratories Ltd. v. Janssen Pharmaceutica, N.V.

Docket: 21-1071

Opinion Date: March 12, 2021

Judge: Kimberly Ann Moore

Areas of Law: Intellectual Property, Patents

Janssen sued Mylan for infringing claims in the 906 patent. Less than six months later, Mylan petitioned for inter partes review (IPR) of that patent, raising four grounds for the unpatentability under 35 U.S.C. 103. Opposing institution, Janssen claimed IPR would be an inefficient use of Patent Trial and Appeal Board resources because of two co-pending district court actions: the suit against Mylan and another suit against Teva. The Board agreed and denied the petition. Applying its six-factor standard, the Board found substantial overlap between the issues raised in Mylan’s IPR petition and the co-pending district court actions and that both actions would likely reach final judgment before any final written decision. The Teva trial date was only weeks away. Mylan argued that the Board’s determination, based on the timing of separate litigation to which Petitioner is not a party, undermines its constitutional and other due process rights and that the Board’s continued adoption and application of non-statutory institution standards through ad hoc proceedings lie in contrast to congressional intent. The Federal Circuit denied relief, stating that it lacks jurisdiction over appeals from decisions denying institution. Although the court has jurisdiction over mandamus petitions challenging such decisions, Mylan has not shown it is entitled to such an extraordinary remedy.